Nicklasson was appointed Chair of the Kymab Board in June 2017. He has held a number of senior positions at AstraZeneca plc including Executive Vice President of Global Marketing and Business Development and EVP of Global Drug Development. He was CEO of Biovitrum AB and Swedish Orphan Biovitrum AB and is currently Chair of the boards of Orexo AB and Zealand Pharma A/S. Dr Nicklasson also serves as a board member of Basilea Pharmaceutica Ltd and Biocrine AB. He previously served as a board member of Scandinavian Life science invest AB, Denator AB, Pozen Inc., Oasmia AB, Farma Investment AS, PledPharma AB, BioInvent International AB, Premier Research Group Ltd and EffRx Pharmaceuticals SA. He is a certified pharmacist and holds a PhD in Pharmaceutical Technology from the Uppsala University, where he is Associate Professor at the Department of Pharmaceutics.  Nicklasson was appointed Chair of the Kymab Board in June 2017. He has held a number of senior positions at AstraZeneca plc including Executive Vice President of Global Marketing and Business Development and EVP of Global Drug Development. He was CEO of Biovitrum AB and Swedish Orphan Biovitrum AB and is currently Chair of the boards of Orexo AB and Zealand Pharma A/S. Dr Nicklasson also serves as a board member of Basilea Pharmaceutica Ltd and Biocrine AB. He previously served as a board member of Scandinavian Life science invest AB, Denator AB, Pozen Inc., Oasmia AB, Farma Investment AS, PledPharma AB, BioInvent International AB, Premier Research Group Ltd and EffRx Pharmaceuticals SA. He is a certified pharmacist and holds a PhD in Pharmaceutical Technology from the Uppsala University, where he is Associate Professor at the Department of Pharmaceutics.

fermentation